Abstract
Background
The atherosclerotic process progresses more dynamically in hemodialysis (HD) patients than in the general population. In HD patients, lower magnesium levels were reported to be associated with increased atherosclerosis of the common carotid artery. We tested the hypotheses that magnesium supplementation helps to improve carotid intima media thickness (IMT) in HD patients.
Materials and methods
A total of 47 patients on HD were included in the study. Patients were randomly divided into two groups: group A (Mg group), in which patients were given magnesium citrate orally at a dosage of 610 mg every other day for 2 months and group B (control group), in which patients received only calcium acetate therapy as a phosphate binder. At baseline and 2 months later, all patients underwent a carotid artery ultrasound scan to measure carotid IMT.
Results
At the end of 2 months, mean serum calcium, phosphorus, and calcium × phosphorus product were not changed in both groups. As expected, mean serum Mg level significantly increased in the Mg group at the end of 2 months. In addition, serum parathyroid hormone (PTH) level significantly decreased in the Mg group at the end of 2 months (P = 0.003). Baseline carotid IMT was similar between the groups. Bilateral carotid IMT was significantly improved in patients treated with magnesium citrate compared to initial values (P = 0.001 for left, P = 0.002 for right).
Conclusion
Based on the present data, magnesium may play an important protective role in the progression of atherosclerosis in patients on dialysis. Further studies are needed to assess more accurately the role of magnesium in atherosclerotic regression in dialysis patients.
Similar content being viewed by others
References
Collins AJ, Li S, Ma JZ et al (2001) Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 38(4) (Suppl 1):26–29. doi:10.1053/ajkd.2001.27392
Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9(Suppl 12):16–23. doi:10.1159/000051199
United States Renal Data Systems (2006) Annual data report. US, Minneapolis, MN
Soubassi LP, Chiras TC, Papadakis ED, Poulos GD, Chaniotis DI, Tsapakidis IP, Soubassi SP, Zerefos SN, Zerefos NS, Valis DA (2006) Incidence and risk factors of coronary heart disease in elderly patients on chronic hemodialysis. Int Urol Nephrol 38(3–4):795–800
Vanholder R, Meert N, Schepers E et al European Uremic Toxin Work Group(EUTox) (2007) Review on uraemic solutes II–variability in reported concentrations: causes and consequences. Nephrol Dial Transplant 22:3115–3121. doi:10.1093/ndt/gfm151
Bots ML, Hoes AW, Koudstaal PJ et al (1997) Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam study. Circulation 96:1432–1437
Buzello M, Törnig J, Faulhaber J et al (2003) The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 14:311–316. doi:10.1097/01.ASN.0000045048.71975.FC
Schwarz U, Buzello M, Ritz E et al (2000) Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15:218–223. doi:10.1093/ndt/15.2.218
Covic A, Mardare N, Gusbeth-Tatomir P et al (2006) Increased arterial stiffness in children on haemodialysis. Nephrol Dial Transplant 21:729–735. doi:10.1093/ndt/gfi196
Massy ZA, Ivanovski O, Nguyen-Khoa T et al (2005) Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 16:109–116. doi:10.1681/ASN.2004060495
Bursztyn M, Motro M, Grossman E et al (2003) Accelerated coronary artery calcification in mildly reduced renal function of high-risk hypertensives: a 3-year prospective observation. J Hypertens 21:1953–1959. doi:10.1097/00004872-200310000-00024
Block GA, Hulbert-Shearon TE, Levin NW et al (1998) Association of serum phosphorus and calciumxphosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607–617. doi:10.1053/ajkd.1998.v31.pm9531176
Ganesh SK, Stack AG, Levin NW et al (2001) Association of elevated serum PO(4), CaxPO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131–2138
Wei M, Esbaei K, Bargman JM, Oreopoulos DG (2006) Inverse correlation between serum magnesium and parathyroid hormone in peritoneal dialysis patients: a contributing factor to adynamic bone disease? Int Urol Nephrol 38(2):317–322
Liao F, Folsom AR, Brancati FL (1998) Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 136:480–490. doi:10.1016/S0002-8703(98)70224-8
Ma J, Folsom AR, Melnick SL et al (1995) Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities study. J Clin Epidemiol 48:927–940. doi:10.1016/0895-4356(94)00200-A
Wei M, Esbaei K, Bargman J (2006) Relationship between serum magnesium, parathyroid hormone, and vascular calcification in patient on dialysis: a literature review. Perit Dial Int 26:366–373
Tzanakis I, Virvidakis K, Tsomi A et al (2004) Intra- and extracellular magnesium levels and atheromatosis in hemodialysis patients. Magnes Res 17:102–108
Lindeman RD (1986) Chronic renal failure and magnesium metabolism. Magnesium 5:293–300
Guillot AP, Hood VL, Runge CF et al (1982) The use of magnesium–containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron 30:114–117
Fabbian F, Cacici G, Franceschini L et al (2007) The relationship between carotid and coronary atherosclerotic damage in dialysis patients. Int J Artif Organs 30:315–320
Kawagishi T, Nishizawa Y, Konishi T et al (1995) High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int 48:820–826. doi:10.1038/ki.1995.356
Grobbee DE, Bots ML (1994) Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 236:567–573
Lorenz MW, Markus HS, Bots ML et al (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115:459–467. doi:10.1161/CIRCULATIONAHA.106.628875
Parfrey PS, Foley RN (1999) The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10:1606–1615
Nishizawa Y, Shoji T, Kawagishi T et al (1997) Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int 62:90–92
Altura BT, Brust M, Bloom S et al (1990) Magnesium dietary intake modulates blood lipid levels and atherogenesis. Proc Natl Acad Sci USA 87:1840–1844. doi:10.1073/pnas.87.5.1840
Mazur A, Maier JA, Rock E et al (2007) Magnesium and the inflammatory response: potential physiopathological implications. Arch Biochem Biophys 458:48–56. doi:10.1016/j.abb.2006.03.031
Malpuech-Brugère C, Nowacki W, Gueux E et al (1999) Accelerated thymus involution in magnesium-deficient rats is related to enhanced apoptosis and sensitivity to oxidative stress. Br J Nutr 81:405–411
Rukshin V, Azarbal B, Shah PK et al (2001) Intravenous magnesium in experimental stent thrombosis in swine. Arterioscler Thromb Vasc Biol 21:1544–1549. doi:10.1161/hq0901.094493
Touyz RM (2003) Role of magnesium in the pathogenesis of hypertension. Mol Aspects Med 24:107–136. doi:10.1016/S0098-2997(02)00094-8
Boskey AL, Posner AS (1980) Effect of magnesium on lipid-induced calcification: an in vitro model for bone mineralization. Calcif Tissue Int 32:139–143. doi:10.1007/BF02408533
Altura BM, Altura BT, Gebrewold A et al (1984) Magnesium deficiency and hypertension: correlation between magnesium-deficient diets and microcirculatory changes in situ. Science 223:1315–1317. doi:10.1126/science.6701524
Meema HE, Oreopoulos DG, Rapoport A (1987) Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 32:388–394. doi:10.1038/ki.1987.222
Ouchi Y, Tabata RE, Stergiopoulos K et al (1990) Effect of dietary magnesium on development of atherosclerosis in cholesterol-fed rabbits. Arteriosclerosis 10:732–737
Orimo H, Ouchi Y (1990) The role of calcium and magnesium in the development of atherosclerosis. Experimental and clinical evidence. Ann N Y Acad Sci 598:444–457. doi:10.1111/j.1749-6632.1990.tb42315.x
Abbott RD, Ando F, Masaki KH (2003) Dietary magnesium intake and the future risk of coronary heart disease (the Honolulu Heart Program). Am J Cardiol 92:665–669. doi:10.1016/S0002-9149(03)00819-1
Neglen P, Qvarfordt P, Eklof B (1985) Peroral magnesium hydroxide therapy and intermittent claudication—a preliminary report. Vasa 14:285–288
Tahara H, Nishizawa Y (2007) Hypomagnesemia and hypoparathyroidism. Clin Calcium 17:1200–1204
Navarro-González JF (1998) Magnesium in dialysis patients: serum levels and clinical implications. Clin Nephrol 49:373–378
Navarro JF, Mora C, Jiménez A (1999) Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients. Am J Kidney Dis 34:43–48. doi:10.1016/S0272-6386(99)70106-X
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Turgut, F., Kanbay, M., Metin, M.R. et al. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 40, 1075–1082 (2008). https://doi.org/10.1007/s11255-008-9410-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-008-9410-3